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Pediatric patients with acute myeloid leukemia (AML) mainly receive myeloablative conditioning regimens
based on busulfan (BU) or total body irradiation (TBI) before allogeneic hematopoietic cell transplantation
(allo-HCT); however, the optimal conditioning regimen remains unclear. To identify which of these regimens
is better for pediatric patients, we performed a retrospective analysis of nationwide registration data
collected in Japan between 2006 and 2011 to assess the outcomes of patients receiving these regimens before
a ﬁrst allo-HCT. Myeloablative conditioning regimens based on i.v. BU (i.v. BU-MAC) (n ¼ 69) or TBI (TBI-MAC)
(n ¼ 151) were compared in pediatric AML patients in ﬁrst or second complete remission (CR1/CR2). The
incidences of sinusoid obstruction syndrome, acute and chronic graft-versus-host disease, and early non-
relapse mortality (NRM) before day 100 were similar for both conditioning groups; however, the incidence of
bacterial infection during the acute period was higher in the TBI-MAC group (P ¼ .008). Both groups showed a
similar incidence of NRM, and there was no signiﬁcant difference in the incidence of relapse between the
groups. Univariate and multivariate analyses revealed no signiﬁcant differences in the 2-year relapse-free
survival rates for the i.v. BU-MAC and TBI-MAC groups in the CR1/CR2 setting (71% versus 67%, P ¼ .36;edgments on page 2146.
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H. Ishida et al. / Biol Blood Marrow Transplant 21 (2015) 2141e21472142hazard ratio, .73; 95% CI, .43 to 1.24, respectively). TBI-MAC was no better than i.v. BU-MAC for pediatric AML
patients in remission. Although this retrospective registry-based analysis has several limitations, i.v. BU-MAC
warrants further evaluation in a prospective trial.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION Unfavorable cytogenetics/genetics were deﬁned as either 7-/7q-, 5q-,
Intensive combination chemotherapy results in a 52% to
75% probability of survival for childhood and adolescent
patients with acute myeloid leukemia (AML); however, more
than 30% of patients relapse [1-4]. Although allogeneic he-
matopoietic cell transplantation (allo-HCT) is the most prom-
ising therapy for intractable disease (eg, cytogenetically
unfavorable disease and relapsed disease), the conditioning
regimen (as well as effective control of graft-versus-leukemia
effects) plays an important role in reducing the incidence of
relapse after transplantation [5]. Although pediatric AML
patients often receive myeloablative conditioning (MAC) reg-
imensbasedon totalbody irradiation (TBI) orbusulfan (BU),no
optimal regimen has been devised.
Myeloablative TBI conditioning regimens are associated
with late complications, which manifest as growth retarda-
tion, neurocognitive effects, cataracts, hypothyroidism,
gonadal dysfunction, infertility, and a signiﬁcantly increased
risk of a second malignancy [6,7]. Myeloablative BU condi-
tioning regimens can also result in some of these late com-
plications, although the incidence of growth retardation,
neurocognitive effects, cataracts, thyroid dysfunction, and
second malignancies may be lower [7-10]. Recent studies
show treatment of adult AML patients with i.v. BU results in
better survival than treatment with TBI [11,12]; however, few
reports have examined these regimens in children. Sisler
et al. [13] showed conditioning regimens that include TBI
have no additional beneﬁt of over those that include BU in
pediatric patients beyond ﬁrst complete remission (CR1). A
report by de Berranger et al. [14] demonstrated that disease-
free survival was signiﬁcantly better after BU and cyclo-
phosphamide (CY) than after TBI and CY. However, it should
be noted that the patients in these studies received both i.v.
and oral BU as a MAC regimen. Also, approximately half of
the patients in the latter study received HCT before 2000. On
the other hand, another study showed that i.v. BU failed to
provide a signiﬁcant survival advantage in children with
acute leukemia when compared with oral BU [15].
The efﬁcacy and adverse events associated with i.v.
BU-MAC regimens are unclear, particularly when used to
treat pediatric AML patients. Therefore, the present study
aimed to compare the outcomes for pediatric AML patients
after i.v. BU-MAC or TBI-MAC.
METHODS
Patients and Transplantation
Pediatric patients (aged <18 years) with de novo AML (excluding
AML-M3) who underwent a ﬁrst allo-HCT after either i.v. BU- or TBI-based
MAC in CR1 or second CR (CR2) between January 2007 and December
2012 were recruited for the study. Patients were prospectively enrolled in
the Japanese Data Center for Hematopoietic Cell Transplantation. Patients
with Down’s syndrome, Fanconi anemia, or neuroﬁbromatosis type 1 and
thosewho received a graft after ex vivoTcell depletion or CD34þ selection or
a graft from an HLA-haploidentical donor were excluded. Patients who
received combination regimens comprising TBI and BU were also excluded.
Finally, data from consecutive patients who received HCT after myeloa-
blative TBI combined with cytotoxic drugs (TBI-MAC) or myeloablative i.v.
BU combined with cytotoxic drugs (BU-MAC) were examined. MAC regi-
mens were deﬁned as regimens that included either fractionated TBI >8 Gy
or i.v. BU >6.4 mg/kg [16].complex karyotype, t(6;11), t(6,9), t(16;21), t(9:22), or as fms-like tyrosine
kinase receptor 3 internal tandem duplication. Favorable genetics were
deﬁned as either t(8;21) or inv(16). Intermediate genetics were deﬁned as
neither unfavorable nor favorable [17,18]. Graft-versus-host disease (GVHD)
was graded according to previously published and accepted criteria [19].
Nonrelapse mortality (NRM) was deﬁned as death during continuous
remission, and relapse-free survival (RFS) was deﬁned as survival without
any relapse of the underlying hematological malignancy or death from any
cause.
Statistical Analysis
Pair-wise comparisons of patient, disease, and transplant characteristics
(covariates)wereperformedusingFisher’s exact test (forcategoricalvariables).
Variables considered in the analysis included year of transplantation (2007 to
2009 versus 2010 to 2012), gender, age at the time of transplantation (<10
versus10), FAB classiﬁcation (M0, M1, andM2 versusM4 andM5 versus M6
and M7), disease status (CR1 versus CR2), cytogenetics/genetics risk category
(favorableversusothers), extramedullary/centralnervous system involvement
(negative versus positive), donor status (matched sibling donor versus others),
graft source (bone marrow versus peripheral blood stem cells versus cord
blood), donorerecipient HLA-A, -B, and -DR antigen matching (match versus
mismatch to GVH direction), donorerecipient ABO group matching (major
matching versus major mismatching), donorerecipient gender matching (fe-
male-to-male versus other combinations), donorerecipient cytomegalovirus
status (negative-to-negative versus other combinations), GVHD prophylaxis
(cyclosporine-based prophylaxis versus others), performance status (<2
versus2), comorbidity index (<2 versus 2), and conditioning regimen (i.v.
BU-MAC versus TBI-MAC). Survival was estimated using the Kaplan-Meier
method and log-rank tests, whereas the cumulative incidence between
groups was analyzed using Gray’s test.
Risk factors associated with relapse, NRM, RFS, and conditioning group
were assessed using multivariate Cox and Fine-Gray proportional-hazard
models. Parameters with P < .2 on univariate analysis were included in the
model. NRM was the competing event for relapse, and relapse was the
competingevent forNRM.Any incidenceofdeathor relapsewas thecompeting
event for GVHD onset.
Statistical analyses were performed using STATA 12 (Stata Corp., TX) and
EZR data analysis programs [20]. Statistical signiﬁcance was set at P < .05.
The present study had 71% power for detecting a 15% difference in the 2-year
survival rate between the i.v. BU-MAC and TBI-MAC groups with an error
(2-sided) of .05 [20]. The study was approved by the institutional review
boards of Matsushita Memorial Hospital and by the Japanese Society for
Hematopoietic Cell Transplantation committee.
RESULTS
Patient Characteristics
Data from 220 patients who received either i.v. BU-MAC
(n ¼ 69) or TBI-MAC (n ¼ 151) were analyzed in detail. Intra-
venous BU-MAC comprised BU plus CY or BU plus melphalan
(MEL) either with or without another cytotoxic drug (n ¼ 13
andn¼52, respectively) orothermiscellaneous combinations,
including BU (n¼ 4), whereas TBI-MAC comprised TBI plus CY
or TBI plus MEL either with or without another cytotoxic drug
(n ¼ 107 and n ¼ 42, respectively) or other miscellaneous
combinations, including TBI (n ¼ 2). Preliminary analyses
revealed thatRFSafterTBI andCYanothercytotoxicdrugwas
similar to that after TBI and MEL  another cytotoxic drug
(2-year-RFS: 65%versus 71%, respectively; P¼ .51) and thatRFS
after i.v. BUandCYanother cytotoxic drugwas similar to that
after i.v. BUandMEL anothercytotoxicdrug (2-year-RFS:71%
versus 71%, respectively; P ¼ .87). We therefore compared the
outcomes after i.v. BU-MAC with those after TBI-MAC.
Table 1 summarizes patient characteristics, comorbidities,
and transplant procedures for each conditioning group.
Table 1
Demographic and Clinical Characteristics According to Conditioning Regimen
i.v. BU-MAC
n (%)
TBI-MAC
n (%)
Total
n (%)
P
Patient characteristics 69 (31) 151 (69) 220 (100)
Year of transplant .56
2007-2009 37 (54) 74 (49) 111 (50)
2010-2012 32 (46) 77 (51) 109 (50)
Gender .25
Female 31 (45) 82 (54) 113 (51)
Male 38 (55) 69 (46) 107 (49)
Age at the time of transplant <.001
4 yr 44 (64) 23 (15) 67 (30)
5-9 yr 10 (15) 38 (25) 48 (22)
10 yr 15 (22) 90 (60) 105 (48)
FAB classiﬁcation
M0 4 (6) 15 (10) 19 (9)
M1 7 (10) 29 (19) 36 (16)
M2 10 (14) 58 (38) 68 (31)
M4 8 (12) 18 (12) 26 (12)
M5 12 (17) 16 (11) 28 (13)
M6 4 (6) 6 (4) 10 (5)
M7 19 (28) 5 (3) 24 (11)
Others*/missing data 5 (7) 4 (3) 9 (4)
M0eM2 vs. M4, M5 vs. M6, M7 <.001
M0eM2 21 (30) 102 (68) 123 (56)
M4, M5 20 (29) 34 (23) 54 (24)
M6, M7 23 (33) 11 (7) 34 (15)
Others*/missing data 5 (7) 4 (3) 9 (4)
Disease status at the time of transplant .01
CR1 55 (80) 94 (62) 149 (68)
CR2 14 (20) 57 (38) 71 (32)
Cytogenetics/genetics .055
Favorable 6 (9) 33 (22) 39 (18)
Intermediate 46 (67) 92 (61) 138 (63)
Unfavorable 16 (23) 25 (17) 41 (19)
UA/missing data 1 (1) 1 (1) 2 (1)
Extramedullary involvement/CNS involvement .18/.002
Negative 56/45 (89/65) 140/128 (93/85) 196/173 (89/78)
Positive CNS/total 13/24 (19/35) 11/23 (7/15) 24/47 (11/22)
Donor .49
Matched sibling 17 (25) 31 (21) 48 (22)
Others 52 (75) 120 (79) 172 (78)
Graft .95
Bone marrow 40 (58) 84 (56) 124 (56)
Peripheral blood stem cell 6 (9) 15 (10) 21 (10)
Cord blood 23 (33) 52 (34) 75 (34)
HLA
Match 46 (67) 81 (54) 127 (58) .08
Mismatch 23 (33) 70 (46) 93 (42)
ABO group .64
Major match 22 (32) 43 (28) 65 (3)
Major mismatch 47 (68) 108 (72) 155 (70)
Gender .03
Female to male 20 (29) 24 (16) 44 (20)
Others 37 (54) 107 (71) 144 (65)
Missing data 12 (17) 20 (13) 32 (15)
Cytomegalovirus status .76
Negative to negative 9 (13) 18 (12) 27 (12)
Others 53 (77) 112 (74) 165 (75)
Missing data 7 (10) 21 (14) 28 (13)
GVHD prophylaxis .08
Cyclosporine-based 21 (30) 48 (32) 69 (31)
Tacrolimus-based 44 (64) 102 (68) 146 (67)
Others 4 (6) 1 (1) 5 (2)
Performance status at the time of transplant .03
<2 63 (91) 148 (98) 211 (96)
2 6 (9) 3 (2) 9 (4)
HCT-CI points .79
<2 59 (86) 132 (87) 191 (86)
2 2 (3) 6 (4) 8 (4)
UA/missing data 8 (12) 13 (9) 21 (10)
Median observation period, mo
31 (4-78) 27 (.3-80) 28 (.3-80)
UA indicates unassessable; CNS, central nervous system; HCT-CI, hematopoietic cell transplantation-speciﬁc comorbidity index.
* AML with multilineage dysplasia or acute undifferentiated leukemia.
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Table 2
Transplantation Outcomes
i.v. BU-MAC
(n ¼ 69)
TBI-MAC
(n ¼ 151)
P
Engraftment .44
No 1 4
Yes 99 96
Bacterial infection .008
No 70 50
Yes 30 50
Sinusoidal obstruction syndrome .55
No 30 23
Yes 3 4
UA/missing data 67 73
Day 100 NRM .06
No 100 95
Yes 0 5
Acute GVHD (day 100)
Grades II-IV 32 (21-43) 36 (29-44) .46
Grades III-IV 17 (10-27) 14 (9-20) .53
Chronic GVHD (2 year)
All 33 (22-45) 23 (17-30) .12
Extensive type 12 (6-21) 12 (7-17) .91
Cumulative incidence of relapse*
(2 year)
24 (15-35) 24 (17-31) .95
Cumulative incidence of NRMy
(2 year)
5 (1-13) 10 (6-15) .12
RFSz (2 year) 71 (58-80) 67 (58-74) .36
Values are percents with 95% CIs in parentheses. Factors with P < .2 in the
univariate model are denoted by symbols.
* ABO group major match (match vs. mismatch, P ¼ .08), Cytogenetics/
genetics (favorable vs. intermediate or unfavorable, P ¼ .04), and perfor-
mance status (<2 vs. 2, P ¼ .09).
y Age (<10 yr vs. 10 yr, P ¼ .17), ABO group major match (match vs.
mismatch, P ¼ .14), extramedullary involvement (negative vs. positive,
P ¼ .08), HLA match (match vs. mismatch, P ¼ .003), GVHD prophylaxis
(cyclosporine-based vs. other prophylaxis, P ¼ .17), donor (matched sibling
donor vs. others, P ¼ .08), and year of transplant (2007-2009 vs. 2010-2012,
P ¼ .09).
z Cytogenetics/molecular marker (favorable vs. intermediate or unfavor-
able, P ¼ .10) and HLA match (match vs. mismatch, P ¼ .16).
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received HCT after i.v. BU-MAC and TBI-MAC, respectively. A
total of 10GyTBI in4or 5 fractions (1 recipient each); 12GyTBI
in 4 (9 recipients), 5 (6 recipients), or 6 fractions (133 re-
cipients); and 13.2 Gy TB1 in 6 fractions (1 recipient) was
administered. However, we have no information about
whether BU was targeted to a certain level. Only 2 patients in
each conditioning group received antithymocyte globulin as
partof the conditioning regimen. Themedianageat the timeof
transplantation was 9 years (range, 0 to 17 years). Of the 218
patients (99%) with assessable cytogenetics and/or genetics,
18%, 63%, and 19% fell into the favorable, intermediate, and
unfavorable categories, respectively. Four patients who had
favorable cytogenetics without induction delay underwent
HCT in CR1, despite the absence of any formal indications. The
median interval from diagnosis to transplantation was
5.5 months for those in CR1 and 19 months for those in CR2.
The median follow-up time was 28 months (range, .3 to 80).
There were signiﬁcant differences between groups in terms of
age at the time of transplantation (P< .001), FAB classiﬁcation
(P< .001), disease status (P¼ .01), extramedullary involvement
(P ¼ .002), recipient and donor gender combination (P ¼ .03),
and performance status (P ¼ .03).
There was no difference in the actuarial incidence of
engraftment, sinusoidal obstruction syndrome, and cumula-
tive incidence of NRMup until day 100 between the 2 groups.
The graft source for 5 of 6 engraftment failure cases was cord
blood. The group conditioned with i.v. BU-MAC experienced
fewer bacterial infectious than the group conditioned with
TBI-MAC (30% versus 50%, respectively; P ¼ .008). The cu-
mulative incidence of grades II to IV acuteGVHDwas 32% (95%
conﬁdence interval [CI], 21% to 43%) and 36% (95% CI, 29% to
44%) (P¼ .46) and of extensive chronic GVHDwas 12% (95% CI,
6% to 21%) and 12% (95% CI, 7% to 17%) (P ¼ .91) in the i.v. BU-
MAC and TBI-MAC groups, respectively (Table 2, Figure 1A,B).
The 2-year cumulative incidences of relapse and NRM
were 24% (95% CI,18% to 30%) and 8% (5% to 12%), respectively,
and the 2-year RFS ratewas 68% (95%CI, 61% to74%): 67% (95%
CI, 59% to 74%) in CR1 and 69% (95% CI, 5% to 79%) in CR2. The
main cause of death was relapse (57% in the BU-MAC group
and 51% in the TBI-MAC group). Both groups were balanced
with respect to cause of death (Table 3; P ¼ .75).
Incidence of Relapse and NRM after Each Conditioning
Regimen
The 2-year cumulative incidence of relapse in the i.v. BU-
MAC group was 24% (95% CI, 15% to 35%) and in the TBI-MAC
group was 24% (95% CI, 17% to 31%) (P ¼ .95); the cumulative
incidencesofNRMwere5% (95%CI,1% to13%) and10% (95%CI,
6% to 15%) (P ¼ .12), respectively (Figure 2A,B). The rate of
relapse differed signiﬁcantly according to cytogenetics/ge-
netics in that the 2-year cumulative incidence of relapse was
11% (95% CI, 3% to 23%) in the favorable cytogenetics/genetics
group versus 27% (95% CI, 20% to 34%) in the nonfavorable
cytogenetics/genetics group (P ¼ .049). NRM differed signiﬁ-
cantly according to HLA matching in that the 2-year cumu-
lative incidence of NMR was 3% (95% CI, 1% to 8%) in the
HLA-matched group versus 15% (95% CI, 9% to 24%) in the
HLA-mismatched group (P ¼ .003).
Multivariate analysis revealed no signiﬁcant association
between the rates of relapse or NRM after i.v. BU-MAC or TBI-
MAC (relapse: hazard ratio [HR], .85; 95% CI, .47 to 1.54;
P¼ .59; NRM:HR, .70; 95% CI, .18 to 2.78; P¼ .61, respectively).
However, NRM rates were signiﬁcantly higher in the
HLA-mismatchedgroup (HR, 3.87; 95%CI,1.15 to 13.1; P¼ .03).RFS after Each Conditioning Regimen
There was no difference in 2-year RFS in the setting of
CR1/CR2 (71% [95% CI, 58% to 80%] versus 67% [95% CI, 58% to
74%] for the TBI-MAC and TBI-MAC groups, respectively;
P ¼ .36) (Figure 2C). The overall survival rates in the i.v. BU-
MAC and the TBI-MAC groups were 80% (95% CI, 68% to
88%) and 73% (95% CI, 65% to 80%), respectively, (P ¼ .12).
Multivariate analysis revealed no signiﬁcant differences
in the RFS rates for the i.v. BU-MAC and TBI-MAC groups (HR,
.73; 95% CI, .43 to 1.24; P ¼ .24). The RFS rates for the inter-
mediate and unfavorable cytogenetics/genetics groups (HR,
2.34; 95% CI, 1.06 to 5.15; P ¼ .03) were signiﬁcantly lower
than those for the favorable group.
RFS According to Other Factors
There was no difference in RFS between grafts from
matched sibling donors and those from unrelated donors
when transplanted after BU-MAC (2-year RFS: 58% versus
75%, respectively; P ¼ .15) and when transplanted after
TBI-MAC (2-year RFS: 74% versus 65%, respectively; P ¼ .37).
Although the number of patients was small, the RFS for
patients with central nervous system disease or advanced
disease (>CR1) was similar after TBI-MAC and BU-MAC
(2-year RFS: 64% versus 77%; P ¼ .54, and 68% versus 71%;
P ¼ .80, respectively).
DISCUSSION
Prospective [21], retrospective [22,23], and meta-analysis
[24] studies provide no clear answer regarding the
Figure 1. (A) The cumulative incidence of grades II to IV acute GVHD was 32% (95% CI, 21% to 43%) in the i.v. BU-MAC group (n ¼ 69; dotted line) and 36% (95% CI, 29%
to 44%) (P ¼ .46) in the TBI-MAC group (n ¼ 151; solid line). (B) The cumulative incidence of extensive chronic GVHD was 12% (95% CI, 6% to 21%) in the i.v. BU-MAC
group (dotted line) and 12% (95% CI, 7% to 17%; P ¼ .91) in the TBI-MAC group (solid line).
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suggest that adult AML patients conditioned with TBI-MAC
experience a lower incidence of relapse [21-24]. A meta-
analysis of 18 trials (3172 leukemia patients) indicated that
TBI-MAC regimens lead to lower rates of relapse in patients
with AML (713 patients in 3 trials); higher rates of NRM in
patients with acute lymphoblastic leukemia, AML, or chronic
myeloid leukemia (2586 patients in 8 trials); and higher rates
of disease-free survival in patients with AML (1289 patients
in 4 trials) [25]. However, all these studies mainly recruited
patients who were conditioned with oral BU. A recent
retrospective analysis indicated that i.v. BU-MAC yielded
similar RFS and overall survival rates to TBI-MAC when used
to condition adult AML patients (over 18 years old); however,
although the rates of NRM were similar, the rates of relapse
were higher [26]. Another retrospective analysis from the
Center for International Blood and Marrow Transplant
Research showed that for patients with AML in CR1, i.v. BU
and CY conditioned groups had better RFS and overall sur-
vival than TBI and CY conditioned groups, with similar rates
of relapse and a better NRM [12]. Furthermore, Bredeson
et al. [11] conducted a prospective nonrandomized trial
involving patients with AML, myelodysplastic syndrome, or
chronic myelogenous leukemia in remission (all patients
were60 years old) and showed that i.v. BU-MAC resulted in
superior overall survival (but not RFS) without an increased
risk of relapse or NRM.
However, the utility of i.v. BU-MAC for pediatric AML
patients remains unclear. In the ﬁeld of pediatric AML, Sisler
et al. [13] showed that TBI for pediatric AML patients beyond
CR1 (n ¼ 151) had no advantages over oral or i.v. adminis-
tration of BU. Recently, a French group compared BU and TBI
for pediatric AML cases in CR1 (n ¼ 226) and found survivalTable 3
Cause of Death
Cause BU-MAC
(n ¼ 14)
TBI-MAC
(n ¼ 45)
Leukemia 8 (57%) 23 (51%)
GVHD 1 (7%) 8 (18%)
Infections 1 (7%) 5 (11%)
Organ failure 1 (7%) 5 (11%)
Graft failure 2 (14%) 3 (7%)
Others 1 (7%) 1 (2%)was signiﬁcantly better for those receiving oral or i.v. BU
(16 mg/kg for oral BU or i.v. BU adapted to recipient body
weight) and CY (200 mg/kg) than for those receiving TBI
(fractionated, 12 Gy) and CY (120 mg/kg), with a more
favorable NRM [14]. Here, we expected to ﬁnd superior (or at
least comparable) outcomes for the i.v. BU-MAC group;
however, we found that the incidences of relapse, NRM, and
RFS after i.v. BU-MAC were similar to those after TBI-MAC in
the setting of CR1/CR2.
There are possible explanations for the differences
between our ﬁndings and those of others. First, although
previous studies showed that BU-MAC was better than
TBI-MAC for AML patients in CR1 and for patients with
myelodysplastic syndrome or chronic myeloid leukemia
[11,12,14], there was no survival advantage for AML patients
in CR2 [13]. Here, we undertook a combined analysis of AML
patients in CR1/CR2, which may be a reasonwhy i.v. BU-MAC
failed to show superior survival rates. Also, the present study
was underpowered with respect to detecting signiﬁcant as-
sociations in the setting of CR1 alone. Second, the RFS rates in
the TBI-MAC group in the present study were better than
those reported by previous studies [13,14]. It is likely that the
tight control of acute GVHD contributed to the low incidence
of NRM in both the TBI-MAC and i.v. BU-MAC groups,
resulting in favorable RFS rates. Because AML shows only
modest sensitivity to acute GVHD and because limited
sensitivity to chronic GVHD and relevant reductions in
relapse rates were only observed in patients experiencing
extensive chronic GVHD [27], the similar relapse rates and
rates of extensive chronic GVHD observed in the 2 groups
suggest that i.v. BU-MAC and TBI-MAC exert comparable
antileukemic effects. Moreover, the lower NRM rates in the
BU-MAC group may be due to factors such as younger age
[13,28] and more patients being in CR1. The similar relapse
rates between the groups may be because more patients
were in CR1 but had unfavorable cytogenetics proﬁles in the
BU-MAC group [29].
BU-MAC is believed to cause early toxicity and higher rates
of sinusoidal obstruction syndrome than TBI-MAC [11]. How-
ever, Nagler et al. [26] showed that TBI- and BU-MAC carried a
comparable risk of sinusoidal obstruction syndrome in AML
patients. Intravenous BU-MAC appeared not to be a risk factor
for transplantation when the i.v. dose was adjusted according
to the target level of the drug or body weight. We found no
Figure 2. (A) The cumulative incidence of relapse. The 2-year cumulative incidence of relapse in the i.v. BU-MAC group (n ¼ 69; dotted line) was 24% (95% CI, 15% to
35%) and in the TBI-MAC group (n ¼ 151; solid line) was 24% (95% CI, 17% to 31%; P ¼ .95). (B) Cumulative incidence of NRM. The 2-year cumulative incidences of NRM
in the i.v. BU-MAC (dotted line) and TBI-MAC (solid line) groups were 5% (95% CI, 1% to 13%) and 10% (95% CI, 6% to 15%), respectively (P ¼ .12). (C) Probability of RFS.
The 2-year RFS rates in the BU-MAC (dotted line) and TBI-MAC (solid line) groups were 71% (95% CI, 58% to 80%) and 67% (95% CI, 58% to 74%), respectively (P ¼ .36).
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BU-MAC group; indeed, both the incidence and cause of death
were similar to those reported by Sisler et al. [13]. The follow-
updurationwas too short to allowus to compare the incidence
of delayed complications between groups. However, previous
reports suggest that BU-MAC is associated with lower rates of
long-term morbidity such as growth and developmental
problems, cataracts, hypothyroidism, hypertension, late car-
diovascular events, and secondary malignant neoplasms
[6-10]. These outcomes support the use of i.v. BU-MAC for
pediatric patients, even if survival rates after i.v. BU-MAC are
similar to those after TBI-MAC.
Here, we used CY in combination with TBI or MEL in
combination with BU in most cases (77% and 73%, respec-
tively) because HCT using a combination of BU plus MEL
followed by an infusion of allogeneic marrow from an
HLA-matched related donor achieves good RFS with mini-
mal mortality and morbidity for patients with good-risk
leukemia [30]. The AML-99 study (and the subsequent
AML-05 study) in Japan recommended that patients in the
CR1 setting receive a combination of BU plus MEL as a
conditioning regimen if they had high- or intermediate-
chromosome risk AML and an HLA-matched sibling donor
[4]. This conditioning regimen has been widely used for
AML patients in the CR1 setting in Japan. However, the
present study (which comprised a small number of pa-
tients) failed to demonstrate that the combination of i.v. BU
plus MEL was superior to i.v. BU plus CY, although neither
showed excessive toxicity. On the other hand, a previous
study reported that a combination of 3 alkylators (BU, CY,
and MEL) was superior to other conditioning regimens (eg,
BU and CY) for children with AML in the CR2 setting [31].
Furthermore, some studies report no signiﬁcant difference
in the relapse rate and a lower incidence of NRM or grade II
to III regimen-related toxicity between BU-CY and
ﬂudarabine-BU regimens when used to treat patients with
AML/myelodysplastic syndrome, especially in the CR1
setting [32,33]. Both CY and ﬂudarabine are used primarily
because of their immunosuppressive, rather than their
antileukemic, properties (ie, to increase engraftment) [32].
Because MEL has profound stem cell toxic and immuno-
suppressive properties, we believe it is reasonable to
replace CY with MEL plus BU for patients with malignancies
whose origin is attributable to a hematopoietic stem cell
defect (eg, AML) [31]. Further prospective and controlledtrials are warranted to evaluate the optimal combinations
of BU and other drugs for patients with AML.
In conclusion, the results of the present study suggest that
i.v. BU-MAC is a promising alternative to TBI-MAC for pedi-
atric AML patients in remission. Nonetheless, this retro-
spective registry-based analysis has several limitations. First,
we do not know why individual patients were selected to
receive speciﬁc conditioning regimens, and there were dif-
ferences in the supportive care provided by individual phy-
sicians. Second, the lack of information about whether BU
was targeted to a certain level may have skewed the results.
This is because evenwhen administered i.v., variable rates of
BU clearance may result in either inadequate or excessive
systemic exposure to the drug. Obtaining targeted BU area
under the curve values via the i.v. route is fundamental to
achieving therapeutic values and for preventing toxicity [34].
It appears likely that improvements in BU administration,
including i.v. administration and dose adjustment, are
responsible for the improved results observed with BU-MAC
[12]. More recently, pediatric AML patients have received
reduced-toxicity conditioning regimens. Antileukemic
effects after allo-HCT conditioned by reduced-toxicity con-
ditioning regimens are comparable with those after condi-
tioning with standard MAC regimens [35,36]. Until a
prospective trial is conducted, the observations reported
herein support the use of i.v. BU-MAC rather than TBI-MAC
for pediatric AML patients in remission.
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